A.I.'s promised scientific revolution faces scrutiny. Despite bold claims from leading A.I. labs, tangible breakthroughs remain limited. Edison Scientific, a company developing A.I. tools for research, recently launched Kosmos, an A.I. agent. The company claims Kosmos can complete six months of doctoral-level research in 12 hours.

Sam Rodriques, founder of Edison Scientific, discussed Kosmos' capabilities and limitations. He tempered expectations, stating that A.I.'s ability to cure diseases is currently unrealistic. Rodriques highlighted bottlenecks hindering A.I.'s acceleration of scientific progress.

The launch of Kosmos signals a potential shift in data analysis within scientific research. However, the market impact of A.I. in scientific discovery remains uncertain. Investors are closely watching for verifiable results and return on investment.

Edison Scientific, a for-profit spinoff of the nonprofit FutureHouse, aims to bridge the gap between A.I. capabilities and scientific application. The company's valuation remains undisclosed, but its success hinges on proving Kosmos' effectiveness.

The scientific community awaits independent verification of Kosmos' claims. Future research will focus on addressing the bottlenecks identified by Rodriques, potentially unlocking A.I.'s true scientific potential.